Loading...

ADIL ADIAL PHARMACEUTICALS INC Investments/Divestments 8-K Filing

DL P

DL

ADIAL PHARMACEUTICALS INC

(ADIL)

2023 8-K

Warrant Agreement

Financial Results Update

FDA Meeting Insights

Nasdaq Compliance Notice

Financial Update

Equity Offerings

Increase in authorized shares

Loan Defaults (Secured, Uns...

Equity Offerings

Equity Offerings

Voluntary Delisting

Financial Statements

Rights Offerings

Management Change

Financial Results

Business Development

Corporate Update

Share Sale Agreement

CEO Agreement Update

PK Study Completion

Equity Plan Update

Management Changes

Entry Into a Material Defin...

Departure of Directors

Warrant Inducement Agreement

Appointment of COO

Special Meeting of Stockhol...

Earnings Release

Annual Meeting and Amendmen...

Amendment to Form 8-K Filing

Securities Purchase Agreement

Recasting Financial Informa...

Acquisition Agreement

Investor Conferences

Earnings Reports

Completion of Acquisition o...

Reverse Stock Split

Presentation at Conference

Purchase Agreement with Alu...

Delisting Notice

Earnings Reports

Material Definitive Agreement

Special Meeting of Stockhol...

Financial Results Announcement

Agreement with The Keswick ...

Regulatory Strategy Update ...

Delisting Notice

Securities Purchase Agreement

Regulatory Meetings for AD04

Acquisition Agreement

External Links:

Adial Pharmaceuticals, Inc. has entered into a master services agreement with The Keswick Group, LLC for business consulting services for AD04, with a monthly fee of $22,000 and a performance bonus of 100,000 shares of restricted common stock.

AI Assistant

ADIAL PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.